Neuronetics to acquire Greenbrook TMS in all-stock deal; Q2 revenue down 7%, net loss widens

Neuronetics, Inc.

Q2 revenue $16.5M (-7% YoY); net loss $(9.8)M ($0.33) vs $(4.9)M ($0.17) prior year.
Acquisition of Greenbrook TMS in all-stock deal; pro forma 2023 revenue ~$145M, double stand-alone.
Expects at least $15M annualized cost synergies; Adjusted EBITDA positive in FY2025, cash flow positive.
Secured $50M debt facility with Perceptive Advisors (up to $90M); repaid SLR Capital loan.
Q3 guidance revenue $18.5M-$19.5M; FY2024 revenue $78M-$80M, opex $78M-$80M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.